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Abstract
Background: Recent studies have highlighted the contribution of senescent mesenchymal and epithelial cells in
Idiopathic Pulmonary Fibrosis (IPF), but little is known regarding the molecular mechanisms that regulate the
accumulation of senescent cells in this disease. Therefore, we addressed the hypothesis that the loss of DNA repair
mechanisms mediated by DNA protein kinase catalytic subunit (DNA-PKcs) in IPF, promoted the accumulation of
mesenchymal progenitors and progeny, and the expression of senescent markers by these cell types.
Methods: Surgical lung biopsy samples and lung fibroblasts were obtained from patients exhibiting slowly, rapidly
or unknown progressing IPF and lung samples lacking any evidence of fibrotic disease (i.e. normal; NL). The
expression of DNA-Pkcs in lung tissue was assessed by quantitative immunohistochemical analysis. Chronic
inhibition of DNA-PKcs kinase activity was mimicked using a highly specific small molecule inhibitor, Nu7441.
Proteins involved in DNA repair (stage-specific embryonic antigen (SSEA)-4+ cells) were determined by quantitative
Ingenuity Pathway Analysis of transcriptomic datasets (GSE103488). Lastly, the loss of DNA-PKc was modeled in a
humanized model of pulmonary fibrosis in NSG SCID mice genetically deficient in PRKDC (the transcript for DNA-
PKcs) and treated with Nu7441.
Results: DNA-PKcs expression was significantly reduced in IPF lung tissues. Chronic inhibition of DNA-PKcs by
Nu7441 promoted the proliferation of SSEA4+ mesenchymal progenitor cells and a significant increase in the
expression of senescence-associated markers in cultured lung fibroblasts. Importantly, mesenchymal progenitor cells
and their fibroblast progeny derived from IPF patients showed a loss of transcripts encoding for DNA damage
response and DNA repair components. Further, there was a significant reduction in transcripts encoding for PRKDC
(the transcript for DNA-PKcs) in SSEA4+ mesenchymal progenitor cells from IPF patients compared with normal
lung donors. In SCID mice lacking DNA-PKcs activity receiving IPF lung explant cells, treatment with Nu7441
promoted the expansion of progenitor cells, which was observed as a mass of SSEA4+ CgA+ expressing cells.
Conclusions: Together, our results show that the loss of DNA-PKcs promotes the expansion of SSEA4+
mesenchymal progenitors, and the senescence of their mesenchymal progeny.
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Background
Interstitial lung diseases (ILD) are a group of diseases
characterized by interstitial fibrosing of the lungs leading
to the loss of alveolar function and normal gas exchange
[1]. Idiopathic pulmonary fibrosis (IPF) is the most com-
mon form of ILD, with a median survival of 2–3 years
after diagnosis [2] and limited therapeutic options. Cur-
rently, IPF patients are treated with OFEV or Esbriet,
both of which slow down the progression of this disease,
but many patients ultimately require lung transplant-
ation despite treatment with these drugs. Most IPF
patients that succumb to this disease die due to respira-
tory failure, however approximately 23% of these pa-
tients succumb due to non-respiratory causes, including
ischemic heart failure, bronchogenic carcinoma, infec-
tion and pulmonary embolism [2]. Several studies have
examined mechanisms leading to disrepair in IPF lung
tissues and prevailing mechanisms suggest that epithelial
dysfunction and/or progenitor cell abnormalities leads to
chronic and aberrant activation of mesenchymal cells
that are paramount to disrepair in lung fibrosis [3–5]. In
line with this, a subpopulation of cells expressing the
stage-specific embryonic antigen (SSEA)-4 with the
properties of mesenchymal progenitors were identified
in the lungs of IPF patients and shown to be “disease-
mediating” [6]. Unlike their normal counterparts, IPF
mesenchymal progenitor cells produce daughter cells
that manifest the full spectrum of IPF hallmarks, includ-
ing the ability to form fibrotic lesions in vivo [6]. Inter-
estingly, in cancer, progenitor cells also have
pathological roles by dividing asymmetrically and produ-
cing malignant daughter cells [7]. Although mesenchy-
mal progenitor cells mediate repair and regeneration in
response to injury, in IPF these cells may actually
contribute to disrepair and disease progression.
Several studies have identified the relationship between
DNA damage, DNA repair, and pulmonary fibrosis [8]. In
fact, we have recently reported that loss of clusterin protein
promoted disrepair and senescence in fibrotic lungs via the
loss of DNA damage response and repair pathways [9].
DNA-dependent protein kinase catalytic subunit (DNA-
PKcs), a member of the PI3K related family of enzymes, is a
master regulator of the DNA-damage response [10]. DNA-
PK is a complex of three proteins, consisting of Ku70/Ku80
and the catalytic holoenzyme DNA-PKcs, and is activated
upon binding of Ku70/Ku80 and DNA. Activation induces
its autophosphorylation as well as the phosphorylation of
several other proteins that culminates in cell cycle check-
point activation and DNA repair [11, 12]. DNA-PKcs is also
integral to NHEJ DNA repair, VD-J recombination, anti-
viral responses against DNA viruses, innate DNA sensing
and in telomere maintenance [11–13]. Given the import-
ance of this protein in DNA double strand break repair and
cell cycle checkpoint, many studies have assessed its role in
tumorigenesis. It has been shown that the kinase activity of
DNA-PKcs can act as a negative regulator of p53-mediated
CDKN1A transcription in stressed cells, and subsequently
promoting apoptosis of the affected cells [14]. However,
DNA-PKcs mediated NHEJ repair was observed to pro-
mote radiation resistance of various tumor cells [15]. Con-
sidering our previous data showing the relevance of DNA
damage and loss of DNA damage repair pathways in disre-
pair and senescence in fibrotic lungs [9] and the divergent
activities of DNA-PKcs in physiological and pathological
settings, the objective of this study was to investigate the
role of DNA-PKcs in IPF and lung fibrosis.
In this study we expand upon our previous observa-
tions and demonstrate the loss of DNA-PK in IPF lung
tissues compared to nonfibrotic lungs. The expression of
DNA-PKcs was rarely detected in the nuclei of IPF mes-
enchymal cells and it did not colocalize with hypomethy-
lated CpG DNA (CpG), nor did it regulate CpG-
mediated myofibroblast differentiation in normal or IPF
lung fibroblasts. Chronic inhibition of DNA-PKcs kinase
activity using a highly specific small molecule inhibitor,
Nu7441 [16] promoted the expansion of SSEA4+ mesen-
chymal progenitor cells and a significant increase in the
expression of myofibroblast, senescence-associated and
inflammatory markers in cultured lung fibroblasts.
Importantly, mesenchymal progenitor cells and their
fibroblast progeny derived from IPF patients showed a
loss of transcripts encoding for DNA damage response
and DNA repair components. Further, there was a sig-
nificant reduction in transcripts encoding for PRKDC
(the transcript for DNA-PKcs) in SSEA4+ mesenchymal
progenitor cells from IPF patients compared with nor-
mal lung donors. Transcriptomic, flow cytometric and
immunofluorescence analysis suggested that SSEA4+
mesenchymal progenitor cells expressed the neuroendo-
crine marker, CgA. In a humanized SCID mouse model
of IPF [17], treatment with Nu7441 promoted the
expansion of mesenchymal progenitor cells (observed as
a mass of SSEA4+ CgA+ expressing cells). Collectively,
our results suggest that DNA-Pkcs expression is
decreased in the lungs of IPF patients and its loss pro-
motes the expansion of mesenchymal progenitor cells
and increased expression of senescent markers in
mesenchymal cells.
Methods
Patient samples and primary lung fibroblasts
Normal and IPF surgical lung biopsy samples and
lung fibroblasts were obtained as previously described
[17, 18]. Both normal and IPF lung fibroblasts were
obtained by mechanically dissociating lung biopsy
specimens or explants into sterile tissue culture plates
and pipetting at least 10 times in complete medium
[Dulbecco’s modified Eagle’s medium (DMEM; Lonza,
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Basel, Switzerland) plus 15% fetal bovine serum (Atlas
Biologicals, Inc., Fort Collins, CO), 100 IU of penicil-
lin, 100 μg/mL of streptomycin (Mediatech, Manassas,
VA), 292 μg/mL of l-glutamine (Mediatech), and
100 μg/mL of Primocin (InvivoGen, San Diego, CA)].
Cells were maintained at 37 °C and 10% CO2 and
medium was changed twice a week by carefully aspir-
ating the liquid, retaining the minced tissues in the
flask, and replacing with fresh medium. This process
was repeated until stromal colonies were apparent (1
to 2 weeks), after which the colonies were trypsinized
and passaged 4 to 5 times and fibroblast purity was
confirmed by flow cytometry and/or real-time quanti-
tative PCR analysis for CD45, EpCAM, and CD31.
Normal lung fibroblasts were derived from nonfibrotic
lung samples lacking any evidence of disease. Patients
were diagnosed with IPF using a multidisciplinary, clin-
ical, radiological, and pathological mechanism [19]. The
physiological criteria used to validate disease progression
during the first year of follow-up included a forced vital
capacity (FVC) decrease of greater than or equal to 10%
and a diffusing capacity for carbon monoxide (DLCO)
decrease of greater than or equal to 15% based on base-
line physiological abnormality. Baseline data for each pa-
tient in the study included detailed clinical assessment,
physiological studies, high-resolution computed tomog-
raphy (HRCT), and surgical lung biopsies (SLBs).
Cells and cell culture condition
Lung fibroblasts were cultured in complete medium at
37 °C and 10% CO2. Medium was changed twice a week
and cells were passaged when 70–90% confluency was
reached. For transcriptomic experiments, 2.5 × 105 lung
fibroblasts per well were plated in complete medium
into a 6-well plate overnight at 37 °C and 10% CO2. Cells
were then stimulated with 10 μM CpG (Hycult Biotech)
and/or treated with 500 nM Nu7441 (Selleckchem.com)
for 24 h (acute) or once every 3 days for a total of 25
days. After treatment, images of the cultured cells were
acquired using an EVOS FL inverted microscope at 20x
magnification (Thermo Fisher Scientific). Cells were
then trypsinized for Flow Cytometry or lysed by Trizol™
(Thermo-Fisher Scientific) for qPCR analysis as de-
scribed. For studies assessing Collagen 1, IL-8, IL-1ß and
αSMA protein expression, cells were then stimulated
with 10 μM CpG (Hycult Biotech), 20 ng/ml recombin-
ant TGFß1 (R&D systems) and/or treated with 500 nM
of Nu7441 (Selleckchem.com) for 24 or 72 h.
Immunohistochemistry
Lung tissue was fixed in 10% NBF solution for 24 h and
subsequently transferred into tissue cassettes and kept in
a 70% ethanol solution for approximately 24 h. Lungs
were then processed using routine histology techniques.
Sections (4 μm) were deparaffinized, hydrated and sub-
jected to antigen retrieval in 10 mM Citric acid solution
(pH 6.0). Samples were then stained with rabbit anti-
DNA-PKcs monoclonal antibody (Clone Y393, Abcam)
or rabbit anti-CgA polyclonal antibodies (Abcam) over-
night at 4 °C and processed as previously described [9].
Images were obtained using Zeiss Axio Observer Z1
microscope and the Zeiss Zen 2012 v 1.1.2.0 software
(Zeiss) or ScanScope AT System. The quantification of
DNA-PKcs expression (Integrated Optical Density) was
performed using Image-Pro Premier software.
Immunofluorescence analysis
Lung fibroblasts were plated onto Lab-Tek II Chamber
Slides (Fisher Scientific) and stimulated with 1 μM bio-
tinylated-CpG (Biotin-CpG; InvivoGen) for 24 h at 37 °C
and 10% CO2. Cells were then washed with DPBS and
fixed with 4% paraformaldehyde solution for 10 min at
room temperature. Paraformaldehyde was then washed,
and the cells were permeabilized using 0.5% TritonX-
100 in DPBS for 10 min at room temperature, washed
and blocked using antibody dilution/blocking solution
(DPBS + 2% bovine serum albumin + 2% normal goat
serum + 0.025% sodium azide) for 30 min at room
temperature. Cells were then incubated with rabbit anti-
human-DNA-PKcs monoclonal antibody (Clone Y393,
Abcam) or IgG control antibody overnight at 4 °C, then
washed and incubated with 1:500 diluted Alexa-flour
488-conjugated anti-rabbit (Thermo Fisher Scientific)
and 1:500 diluted Alexa-flour 594-conjugated streptavi-
din (Thermo Fisher Scientific) for 1 hour at room
temperature. Cells were then washed three times with
DPBS and mounted with ProLong Gold Antifade
Mountant with DAPI (Thermo Fisher Scientific). For hu-
man lung tissues, paraffin embedded tissues were de-
paraffinized, rehydrated and subjected to antigen re-
trieval in 10 mM Citric acid solution (pH 6.0). Slides
were then permeabilized using a 10% methanol solution,
blocked and stained using anti-SSEA4 and CgA anti-
bodies (Abcam) overnight at 4 °C. As control, IgG iso-
type antibodies were utilized on serial sections from the
same tissue. The next day, slides were washed three
times with DPBS and once with DPBS containing 0.05%
Tween-20 (DPBS-T), incubated with Alexa-Flour 594
conjugated anti-mouse and Alexa-Flour 488 conjugated
anti-rabbit secondary antibodies (Thermo Fisher Scien-
tific) for 1 h at room temperature. Slides where then
washed three times with DPBS and once with DPBS-T
and mounted with ProLong Gold Antifade Mountant
with DAPI (Thermo Fisher Scientific). A Zeiss Axio Ob-
server Z1 microscope and the Zeiss Zen 2012 v 1.1.2.0
software (Zeiss) were used to obtain representative im-
ages and fluorescence intensity was set based on the
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background fluorescence levels observed in the IgG
stained samples.
Quantitative PCR analysis
Cells were lysed in Trizol™ reagent (Thermo-Fisher
Scientific) and RNA was extracted as recommended by
the manufacturer. One-microgram of RNA was reverse
transcribed into cDNA using superscript II reverse tran-
scriptase (Life technology) as previously described [18].
Complementary DNA (cDNA) was subsequently loaded
into a TaqMan plate (Thermo-Fisher Scientific) and
gene expression analysis were performed using SYBR or
TaqMan master mix (Thermo Fisher Scientific) and
ACTA2 [18], NRF2 [20] or HO1 [20] Sybr primers or
predesigned primers and probes for human-COL1A1,
COL3A1, FN1, VIM, CDKN1A, CDKN1B, NOX4, CCL2,
CXCR4, GAS6, IL1B, IL6, TNF or TNFSF10 (Thermo
Fisher Scientific). For mouse lungs, lung tissues were ho-
mogenized in Trizol™ solution (Thermo Fisher Scientific)
using a microsample homogenizer (Pro Scientific). RNA
was extracted, and cDNA was generated as described
above. Transcriptomic analysis was performed using
ACTA2 [18], ENO2 (ENO2F: TCAGGGACTATCCT
GTGGT; ENO2R: CATTGGCTGTGAACTTGGA),
GLRA1 (GALR1 F: CCATGAGATCACCACAGAC;
GALR1 R: GTCAGGGTGATTCTGATGC) or NOX4
(Nox4 F: CTCAGTCTTTGACCCTCGG; Nox4 R: GGA-
GAGCCAGATGAACAGG) SYBR primers or prede-
signed primers and probes for human-COL17A1,
COL3A1, VIM, CDKN1A and CHGA (Thermo Fisher
Scientific). Quantitative PCR analysis was performed
using a Viia7 thermocycler (Thermo Fisher Scientific)
and the data were analyzed using Data Assist software
version 3.01 (Thermo Fisher Scientific).
Soluble collagen 1, IL-8, IL-1ß and in cell αSMA and ß-
tubulin ELISA analysis
Five-thousand lung fibroblasts per well were plated into
a 96 well plate, stimulated with 10 μM CpG, 20 ng/ml
TGFß and/or treated with 300 nM BIBF1120 (Boehrin-
ger Ingelheim) or 500 nM Nu7441 (Selleckchem.com)
for 24 and 72 h. After stimulation and/or treatment, con-
ditioned supernatants were collected, and the cells were
fixed using 4% paraformaldehyde solution. Collagen-1,
IL-8, IL-1ß, αSMA and ß-tubulin proteins were quanti-
fied as described under the “Soluble Collagen 1, IL-8, IL-
1ß and in cell αSMA and ß-tubulin ELISA analysis”
Cells were then analyzed for αSMA protein expression
using an in-cell ELISA as previously described [21].
ELISA assays were performed to quantify soluble colla-
gen (as previously described [21]) IL-1ß (R&D systems)
and IL-8 proteins (R&D systems) as recommended by
the manufacturer.
Flow cytometry
After Nu7441 treatment, lung fibroblasts were trypsi-
nized for 30–45 s at room temperature. Trypsin was
then inhibited by adding complete medium and the cells
were spun down at 400 x g for 5 min. Cells were resus-
pended in DPBS + 2% FBS (FACS buffer) and blocked
using human TruStain FcX FC receptor blocking solu-
tion (Biolegend) for 15 min on ice. Cells were then
stained with anti-SSEA4-APC antibodies (Biolegend) for
15 min at 4 °C, then washed twice with FACS buffer and
fixed with 5% neutral buffered formalin solution. Flow
cytometric data were acquired using a MACSQuant
analyzer 10 (Miltenyi Biotech) and the data were ana-
lyzed using FlowJo version 10.3 (Flowjo, LLC).
Invasive wound healing analysis
Invasive wound healing assay was performed as previ-
ously detailed [21]. Briefly, 96 well ImageLock™ plates
(Essen BioScience) were pre-coated with Basement
membrane extract (BME, Trevigen, 50 μg/mL) and
maintained at room temperature for at least 1 h. Next,
BME solution was removed from the plates and fibro-
blasts were plated (3.5 × 104/well) and incubated over-
night at 37 °C and 10% CO2. The wells containing cells
were scratched using the WoundMaker™ (Essen Bio-
Science), washed with PBS and then layered with 4 mg/
ml Matrigel containing vehicle or 500 nM Nu7441. Cells
were monitored using an IncuCyte ZOOM live cell
imager (Essen Biosciences) at 37 °C, 10% CO2 for 150 h.
Wound closure was measured using the IncuCyte
ZOOM Software (Essen Biosciences) as relative wound
density [measurement of the spatial cell density in the
wounded area relative to the area outside the wounded
area over time]. 0% represents the wound when there
are no cells in the scratched site at t = 0 and 100% repre-
sents a wound density where the cell density in the
wound is equivalent to the density outside the wound,
i.e. 100% wound healing.
Bioinformatic analysis of publicly available datasets
Previously analyzed publicly available data sets
(GSE103488 [9]) from FACS sorted SSEA4+ versus non-
sorted SSEA4− cells were re-analyzed as follows: IPF
samples utilized in these datasets were divided based on
rate of progression, slow progressing IPF (slow-IPF;
S161, S109, S170 & S76A; n = 4) or rapid progressing
IPF (rapid-IPF; defined as described herein and previous
study [18]; S99, S148, S48, S69, S56 & S180; n = 6), and
fold changes were calculated relative to normal cells
(NL4, NL7 & NL16; n = 3) and the data were analyzed
using Ingenuity integrated pathway analysis (IPA; QIA-
GEN Inc., https://www.qiagenbioinformatics.com/ prod-
ucts/ingenuity- pathway-analysis). Stacked bar graphs of
enriched ingenuity canonical pathways (depicting the
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percentage of transcripts that were upregulated and
down regulated) were set to show all pathways with a
minimum -log(p-value) 3.0 or higher. Stacked bar graphs
were exported and are depicted in the figures.
Mice
Eight-Ten-week-old, female, pathogen free NOD Cg-
PrkdcSCID IL2rgTm1wilSzi (NSG) were ordered from Jack-
son Laboratories. Mice were housed in disposable plastic
cages containing Sani-Chip bedding (n = 4–5 mice per
cage) and allowed to acclimate for a minimum of 7 days
prior to utilization. To model the loss of DNA-PKcs ac-
tivity in xenografted IPF cells in NSG mice (20–25 g),
IPF lung explant cells was intravenously administered as
previously described [17]. Briefly, mice were physically
restrained and 1 × 106 IPF lung explant cell (0.25 mL)
was intravenously injected into the tail vein of each
mouse (n = 4–5 per group). Thirty-five days after admin-
istration, humanized mice were interperitoneally treated
with saline or 10 mg/kg of Nu7441 solution (dissolved at
0.5 mg/ml in DPBS and sonicated in a water bath sonica-
tor), twice a week for a total of 4 weeks. After a total of
7 weeks (63 days), mice were euthanized by inhalational
isoflurane anesthesia overdose, followed by cervical dis-
location. Lung tissues were collected for hydroxyproline,
protein, and transcriptomic analysis. The mass in the
thoracic cavity was micro dissected, fixed and paraffin
embedded for histological analysis. Animals were ran-
domly assigned to the experimental groups and experi-
ments were performed once.
Hydroxyproline assay
Total lung hydroxyproline was quantified and analyzed
as previously described [17].
Western blot analysis
Mouse lung tissues were homogenized in DPBS contain-
ing protease inhibitors (Thermo Fisher Scientific) using
a microsample homogenizer (Pro Scientific). Total pro-
tein content was quantified using a DC Protein assay
(Bio-Rad Laboratories, Inc.) and equal amount of protein
was prepared and loaded onto an 4–15% NuPAGE Bis-
Tris Protein Gel as recommended by the manufacturer
(Thermo-Fisher Scientific). Gels were transferred using
an iBlot Dry blotting system onto nitro-cellulose mem-
branes (Thermo-Fisher Scientific) and the transferred
samples were blocked for 30 min at room temperature
in 5% non-fat-dry-milk in tris-buffered saline (TBS).
Blots were then washed twice and incubated with anti-
alpha-smooth muscle actin antibodies (Sigma-Aldrich)
at 4 °C overnight. The next day, the blots were washed
three times with 0.05% tween-20 containing TBS solu-
tion (TBS-T), incubated with a secondary antibody,
washed three times after incubation and developed using
a chemiluminescent substrate (Thermo-Fisher Scien-
tific). Images of chemiluminescent bands were acquired
using a Bio-Rad Gel documentation system (Bio-Rad
Laboratories, Inc.). The blots were then washed in TBS-
T, blotted with anti-tubulin antibodies (Abcam) and
developed in a similar manner. Densitometric analysis
were performed using Image Lab Software version 6.0
(Bio-Rad Laboratories, Inc.).
Histologic analysis
Left lung tissue was collected and processed as previously
described [17]. Images were obtained using Zeiss Axio
Observer Z1 microscope and the Zeiss Zen 2012 v 1.1.2.0
software (Zeiss) or ScanScope AT System.
Study approval
All experiments with primary human lung tissues and
cell lines derived from these tissues were approved by an
IRB at Cedars-Sinai Medical Center and University of
Michigan (Approval numbers: Pro00034067 and
Pro00044849). Moreover, all patients were informed and
written consent to participate was obtained prior to in-
clusion in the studies. All animal procedures followed
the guidelines of the Animal Welfare Act and the Public
Health Policy on Humane Care and Use of Laboratory
Animals of the United Sates and were approved by the
Institutional Animal Care and Use Committee at Ce-
dars-Sinai Medical Center (IACUC005136).
Statistical analysis
All statistical analyses were performed using GraphPad
Prism software version 7 (GraphPad). Data were
expressed as means ± SEM and assessed for signifi-
cance by One-way ANOVA followed by Tukey’s mul-
tiple comparisons test or Mann-Whitney two-tailed
non-parametric test, as detailed in the figure legends.
P < 0.05 were considered statistically significant.
Results
Loss of DNA-PKcs protein in IPF lung tissues
Recently, we have reported that loss of clusterin protein
was associated with reduced DNA repair capacity and
disrepair in IPF and mouse lung-epithelial cells [9]. Fur-
ther, a recent report has shown that clusterin protein ex-
pression is also down-regulated in IPF lung fibroblasts
[22]. In the present study, DNA-PKcs expression was
assessed in lung tissues from normal and IPF patients
with stable, rapid, and unknown progression of disease
by immunohistochemical analysis. Albeit a relatively low
number of patient samples were assessed (n = 3 per
group), quantification revealed that DNA-PKcs was sig-
nificantly decreased in IPF lungs compared to normal
lungs (Fig. 1a-e). No significant difference was observed
in DNA-PKcs expression between the stable, rapid, and
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unknown progression IPF groups (Fig. 1a-e), suggesting
that DNA-PKcs expression is reduced in IPF compared
with normal, regardless of disease progression.
DNA-PKcs is not required for innate DNA sensing of
hypomethylated CpG DNA by normal and IPF lung
fibroblasts
Lung fibroblasts differentiate into myofibroblasts in re-
sponse to hypomethylated CpG DNA (CpG; [18]) stimu-
lation. Further, several reports have suggested that
DNA-PKcs is activated in response to CpG stimulation
in immune and non-immune cells, where it promotes
type I interferon, IL-6, IL-12 and/or IL-10 expression
[23–25]. With this background, we next determined
whether DNA-PKcs mediated CpG-induced myofibro-
blast differentiation in primary lung fibroblasts. Im-
munofluorescence analysis of cells stimulated with 1 μM
of biotinylated-CpG showed that CpG was predomin-
antly localized in focal cytosolic and perinuclear regions
in normal and IPF lung fibroblasts (Figs. 2b-d, f-h, j-l
and 3n-p) after 24 h. DNA-PKcs was localized in the nu-
cleus of normal and IPF cells (Fig. 2a, e, i & m) at this
time, but this protein rarely co-localized with biotinyl-
ated CpG DNA in normal cells (Fig. 2a-h) and occasion-
ally co-localized with nuclear biotinylated-CpG DNA in
IPF cells (Fig. 2i-p, white arrowheads).
To determine the role of this kinase in CpG-in-
duced myofibroblast differentiation, normal and IPF
lung fibroblasts were activated with 10 μM of CpG
and treated with 500 nM of Nu7441 (a specific DNA-
PKcs small molecule inhibitor [16]) or 300 nM of
BIBF-1120 (a multi-receptor tyrosine kinase inhibitor,
also known as nintedanib and OFEV) for 24 h. Tran-
scriptomic analysis for myofibroblast markers in these
treated cells revealed that CpG induced an increase of
ACTA2 and COL1A1 transcript expression (Fig. 3a-b)
and did not induce any significant changes in
COL3A1 and FN1 transcripts (Fig. 3c-d) in normal
Fig. 1 DNA-PKcs expression is reduced in IPF lung tissues. a-d Shown are representative images of normal (a) and IPF (b-d) lung explants from
patients with stable (b), rapid (c), and unknown (d) progression of disease stained with anti-DNA-PKcs antibodies or IgG control (inlay) antibodies.
e Integrated Optical Density (IOD) of DNA-PKcs IHC staining was quantified using Image-Pro Premier. Groups and scale bars are as indicated on
the images. n = 3 normal, n = 3 Stable IPF, n = 3 Rapid IPF, and n = 3 Unknown IPF. *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.005 compared to normal
lung explants. One-way ANOVA followed by Tukey
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and IPF lung fibroblasts. However, neither Nu7441 or
BIBF-1120 treatment significantly reduced CpG-in-
duced ACTA2 or COL1A1 transcript expression in
normal or IPF lung fibroblasts (Fig. 3a-b). In separate
experiments, cells were stimulated with 10 μM CpG
or 20 ng/ml of TGFß1 in the presence or absence of
500 nM Nu7441 for 24 or 72 h followed by αSMA,
Collagen 1, IL-8 or IL-1ß protein quantification. Sev-
enty-two hours after stimulation, CpG induced a sig-
nificant increase in secreted collagen 1 protein from
one normal lung fibroblast line (Fig. 3f) but did not
consistently modulate the secretion of this matrix pro-
tein from the other fibroblast lines (Fig. 3e & g-h, re-
spectively). TGFß1 stimulation significantly increased
the concentration of secreted collagen 1 in all four
fibroblast lines assessed (Fig. 3e-h). Consistent with the
transcriptomic analysis, Nu7441 treatment did not
modulate CpG-induced collagen 1 secretion (Fig. 3f)
and did not consistently modulate TGFß1-induced col-
lagen 1 secretion, where this inhibitor enhanced
TGFß1-induced collagen 1 secretion in one normal
fibroblast line (Fig. 3f) and inhibited TGFß1-induced
collagen 1 secretion in one IPF fibroblast line (Fig. 3g).
Seventy-two hours after treatment, neither CpG nor
TGFß1 induced consistent IL-8 protein expression and/
or secretion by normal lung fibroblasts (Fig. 3i), how-
ever, TGFß1 promoted IL-8 protein expression and/or
secretion by IPF lung fibroblasts, and this effect was en-
hanced by Nu7441 treatment (Fig. 3j). Further, TGFß1
and, to a lesser extent, CpG, stimulation induced a
Fig. 2 DNA-PKcs does not co-localize with hypomethylated DNA in normal and IPF lung fibroblasts. a-p Normal and IPF lung fibroblasts were
treated with 1 μM biotinylated-hypomethylated CpG DNA (biotin-CpG) for 24 h and then fixed and stained with Alexa-flour 594-conjugated-
strepdavidin and anti-DNA-PKcs followed by Alexa-flour 488 conjugated secondary antibodies. As a control, untreated cells were stained with
Alexa-flour 594-conjugated-strepdavidin and IgG control antibodies. Shown are representative images acquired at 200x magnification showing
the localization of DNA-PKcs (a, e, i & m, green), biotin-CpG (b, f, j & n, red) or DAPI stained nuclei (c, g, k & o, blue) in normal (a-h) and IPF (i-p)
lung fibroblasts. Composite images are shown in panels d, h, l & p for normal and IPF lung fibroblasts, respectively. n = 2 normal and n = 2 IPF.
Scale bars = 50 μm
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modest and Nu7441- insensitive elevation of αSMA
protein expression in normal but not IPF lung fibro-
blasts (Fig. 3k-l). Finally, neither activators nor
Nu7441 treatment induced any consistent changes in
IL-1ß protein expression and/or secretion at 24 h
after IPF lung fibroblast treatment and/or stimulation
(Additional file 1: Figure S1A-B). Collectively, these
results suggest that DNA-PKcs does not regulate
CpG-induced lung fibroblasts myofibroblast differenti-
ation but may be involved in senescence.
Chronic inhibition of DNA-PKcs kinase activity leads to an
expansion of SSEA4+ mesenchymal progenitor cells and
the expression of myofibroblast, senescence-associated
and inflammatory transcripts by lung fibroblasts
To further explore the persistent inhibition of DNA-
PKcs in human lung fibroblasts, cells were treated with
500 nM of Nu7441 once every 3 days for a total of 25
days, after which cells were analyzed via flow cytometry
and transcriptomic analysis. Untreated cells were utilized
as controls. At day 25 after Nu7441 treatment, lung
Fig. 3 DNA-PKcs kinase activity is not required for innate DNA sensing by lung fibroblasts. a-d Lung fibroblasts were stimulated with 10 μM of
hypomethylated CpG DNA (CpG) and/or treated with 500 nM Nu7441 or 300 nM BIBF-1120 for 24 h. After 24 h, RNA was extracted and
transcriptomic analysis for myofibroblasts markers were performed. Shown is the average fold change of ACTA2 (a), COL1A1 (b), COL3A1 (c) & FN1
(d) transcript expression in CpG stimulated and/or Nu7441 or BIBF-1120 treated relative to untreated lung fibroblasts. n = 3 normal; n = 5 IPF.
Data shown are mean ± s.e.m.; **p ≤ 0.01 as indicated by the bar. 2-way ANOVA followed by Tukey’s multiple comparisons test. e-h Lung
fibroblasts were stimulated with 10 μM CpG or 20 ng/ml TGF-ß1 and/or treated with 500 nM Nu7441 for 72 h. Shown is the average
concentration of secreted collagen 1 protein by two normal (e-f) and two IPF (g-h) lung fibroblasts treated in triplicate. Data shown are mean ±
s.e.m. *p ≤ 0.05, **p ≤ 0.01, and ****p ≤ 0.0001 compared to vehicle group or as indicated by the bars. One-way ANOVA followed by Tukey’s
multiple comparisons test. i-j Shown is the average fold change of IL-8 protein, secreted by normal (i) and IPF (j) lung fibroblasts 72 h after
stimulation and/or Nu7441 treatment relative to vehicle treated cells. k-l Seventy-two hours after stimulation and/or treatment, cells were fixed,
permeabilized and stained with anti-αSMA and ß-tubulin antibodies. Shown is the average ß-tubulin normalized expression of αSMA protein in
stimulated and Nu7441 treated normal (k) or IPF (l) fibroblasts relative to their respective vehicle treated groups. i-l Data shown are mean ± s.e.m.
n = 2 normal and n = 2 IPF treated in triplicate. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001 compared to vehicle group or as indicated
by the bar. One-way ANOVA followed by Tukey’s multiple comparisons test
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fibroblasts were morphologically distinct compared to
untreated cells (Fig. 4a-b), most notably cells treated
with the inhibitor were more hyperplastic relative to
their untreated counterparts. Flow cytometric analysis
showed that there was a significant change in the per-
centage of SSEA4+ progenitor cells in Nu7441-treated
cultures compared with untreated cultures (Fig. 4c-d).
Transcriptomic analysis of Nu7441-treated and un-
treated fibroblasts showed that this treatment caused a
significant increase in the myofibroblast-associated
ACTA2 & VIM (Fig. 4e), the senescence-associated
CDKN1A, CDKN1B, CDKN2A, NOX4 (Fig. 4f), and the
stress-response and pro-inflammatory transcripts NRF2,
CCL2, CXCR4, IL1B and TNFSF10 (Fig. 4g) compared
with untreated cells. Surprisingly, Nu7441 treatment sig-
nificantly reduced COL1A1 transcript relative to un-
treated fibroblasts (Fig. 4e). We then assessed the
modulation of lung fibroblast invasive wound healing by
Nu7441. Treatment of lung fibroblasts with 500 nM of
Nu7441 over 150 h reduced the invasive wound healing
in both normal (Additional file 2: Figure S2A-C) and IPF
lung fibroblast lines (Additional file 2: Figure S2D-E).
Together, these results demonstrate that inhibition of
DNA-PKcs activity enriched for SSEA4+ mesenchymal
progenitor cells, reduced lung fibroblast invasion, and
promoted senescence-associated markers in vitro.
Loss of PRKDC transcript expression and various
components involved in DNA damage response in SSEA4+
mesenchymal progenitor and SSEA4− mesenchymal
progeny cells
Next, we assessed the expression of proteins
involved in DNA repair in normal and IPF lung fi-
broblasts and mesenchymal progenitor cells by re-
analyzing previously published transcriptomic
datasets (GSE103488 [9]) from sorted normal and
IPF SSEA4+ mesenchymal progenitor cells [6, 26]
and SSEA4− fibroblasts based on IPF progression.
The IPF datasets were grouped by progression as fol-
lows: slow progressing IPF (slow-IPF; S161, S109,
S170 & S76A) versus rapid progressing IPF (rapid-
IPF; defined in the methods section and as previ-
ously described [18]; S99, S148, S48, S69, S56 &
S180). Fold-changes were then calculated for each
Fig. 4 Loss of DNA-PKcs kinase activity promotes the expansion SSEA4+ progenitor cells and senescence-associated transcripts. Lung fibroblasts
were cultured and treated with 500 nM of Nu7441 every 3 days for a total of 25 days. As a control, untreated fibroblasts were utilized. a-b Shown
are representative images of untreated (a) or 25-day Nu7441 treated (b) lung fibroblasts. c After 25 days, lung fibroblasts were trypsinized and
stained with anti-SSEA4 antibodies. Shown are representative dot plots depicting SSEA4+ cells within untreated (C, left) and 25-day Nu7441
treated (C, right) fibroblast cultures. d Shown is the mean percentage of SSEA4+ cells in untreated and 25-day Nu7441 treated fibroblast cultures.
Data shown are mean ± s.e.m.; n = 4. *p ≤ 0.05 via Mann-Whitney two-tailed non-parametric test. e-g Twenty-five days after culture with or
without Nu7441, RNA was extracted from lung fibroblasts and qPCR analysis was performed for myofibroblast (e), senescence and stress-
associated (f) and inflammatory (g) transcripts. Depicted is the average fold change of expression of Nu7441 relative to vehicle treated lung
fibroblasts. n = 4; *p ≤ 0.05 via Mann-Whitney two-tailed non-parametric test
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group compared with normal cells and the data were
analyzed using Ingenuity Integrated Pathway Analysis
(IPA). As summarized in Fig. 5, a loss of transcripts
encoding for components of various DNA damage
response and repair proteins were observed in both
rapid-IPF SSEA4+ (Fig. 5a) and SSEA4− cells (i.e.
progeny) (Fig. 5b), including role of BRCA1 in DNA
damage response, ATM signaling, mismatch repair in
eukaryotes, BER pathway and Cell cycle: G2/M DNA
damage checkpoint regulation pathways compared
with the normal mesenchymal progenitors and pro-
geny. However, these pathways were not present fol-
lowing a comparison of SSEA4+ and SSEA4− cells
from slow progressing IPF patients with normal mes-
enchymal cell types (Additional file 3: Figure S3A-B).
Because of the loss of various DNA repair pathways
in progenitor and mesenchymal cells, we next
assessed the expression of PRKDC (encoding for
DNA-PKcs), which is required for DNA damage sig-
naling, double strand break repair, telomere main-
tenance and resistance to oxidative stress [11, 12, 27,
28] in rapid- and slow-IPF SSEA4+ progenitors and
SSEA4− fibroblasts. Mining of transcriptomic data-
sets showed that there was a loss PRKDC transcript
in cells derived from rapid-IPF fibroblast cultures
(Fig. 5c-d). Together, these results suggest that cul-
tured SSEA4+ mesenchymal progenitor and SSEA4−
mesenchymal progeny cells from progressive IPF pa-
tients were characterized by a loss of PRKDC tran-
script expression and various components involved
in DNA damage response and/or DNA damage re-
pair pathways.
Fig. 5 Loss of PRKDC transcript and DNA damage response components in SSEA4+ and SSEA4− IPF fibroblasts. SSEA4+ cells were sorted from
normal and IPF lung fibroblast cultures. RNA was extracted from the sorted cells SSEA4+ and non-sorted SSEA4− cells and subject to RNA
sequencing analysis as previously described (GSE103488 [9]). a-b Shown are Ingenuity canonical pathway analysis of Rapid-IPF versus normal
SSEA4+ cells (a) and Rapid-IPF versus normal SSEA4− cells (b). Ingenuity was set to consider transcripts with an FPKM value ≥0.2 and a fold
change ≥1.5 &≤ − 1.5 (a) and FPKM value ≥1 and a fold change ≥1.5 &≤ − 1.5 (b). Percentage depicts the proportion of transcripts from the
transcriptomic analysis that are annotated in the Ingenuity canonical pathway. The percentage of transcripts that are downregulated or
upregulated in each canonical pathway are depicted in green or red, respectively. c-d Shown are the mean FPKM counts for PRKDC in normal,
slow-IPF and rapid-IPF SSEA4+ progenitors (a) and SSEA4− fibroblasts (b). Data shown are mean ± s.e.m.; n = 2–5/group. *p ≤ 0.05 via Mann-
Whitney two-tailed non-parametric test
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CgA protein is highly expressed by SSEA4+ mesenchymal
progenitor cells and in IPF lung tissues
Given the expansion of SSEA4+ cells in fibroblast
cultures that were treated chronically with Nu7441,
further characterization of these cells was performed.
Several reports have suggested that SSEA4+ cells are
mesenchymal progenitor cells [6, 26] and we have
recently observed that these cells are also enriched
with basal-epithelial cell transcripts [9]. Mining of
transcriptomic datasets (GSE103488 [9]) for add-
itional airway epithelial cell lineage markers showed
that these cells expressed various markers of
neuroendocrine cells, including ENO2, CHGA, SYP
and GLRA1 (Fig. 6a). Further, these markers tended
to be significantly enriched in SSEA4+ cells from
slow-IPF or normal lung fibroblast cultures (Fig. 6a).
Consistently, SSEA4+ cells from normal and IPF
lungs abundantly expressed CgA protein as deter-
mined by intracellular flow cytometric analysis (Fig.
6b-c). Rare CgA or SSEA4 immuno-positive cells
were detected in normal lung tissues (Fig. 6d, top)
but there was an abundance of cells that expressed
both CgA and SSEA4 proteins in IPF lungs (Fig. 6d,
middle and bottom, Additional file 4: Figure S4).
Further, IHC analysis for CgA protein in normal and
IPF lung tissues showed that this protein is rarely
detected in normal lungs (Fig. 6e) but CgA-positive
cells were detected in slow-IPF, rapid-IPF lung biop-
sies (Fig. 6f-g), and most abundant in end stage
lung-explants (Fig. 6h-i). Thus, these results demon-
strate that SSEA4+ mesenchymal progenitor cells ex-
press the neuroendocrine marker, CgA and that
there appears to be an expansion of these cells as
IPF progresses.
Fig. 6 Abundance of CgA expression in SSEA4+ progenitor cells and IPF lung tissues. a SSEA4+ cell RNAseq datasets (GSE103488 [9]) were mined
for the expression of various lineage transcripts. Shown are the average FPKM values from 2 Normal-, 4 slow- and 4 rapid-SSEA4+ cells. b-c
Normal and IPF stromal cultures were permeabilized and stained SSEA4 and CgA followed by flow cytometric analysis. Representative flow
cytometric contour plots derived from 3 normal (b) and 2 IPF (c) stromal cultures stained and gated for SSEA4 (left) showing the expression of
CgA protein in the gated cells (right). d Normal or IPF lung explants were stained for CgA and SSEA4 followed by fluorescently conjugated
secondary antibody and fluorescent microscopy analysis. Representative images from Normal (top) and two IPF patients (bottom two rows) are
shown stained with CgA (left) and SSEA4 (middle) and the merged composite (right) acquired at 200x magnification. e-i Normal (e), slow- (f),
rapid- (g), IPF biopsies or explants (h-i) were histologically stained for CgA. Representative images were taken from 3 normal, 4 slow- & 5 rapid-
IPF biopsies and 12 IPF explants. IgG control staining are shown in inlayed images
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Inhibition of DNA-PKcs activity promoted the expansion
of SSEA4+ CgA+ cells in humanized NSG mice
Our final set of experiments addressed the effects of
DNA-PKcs on lung fibrosis in vivo. Recently, we devel-
oped a novel humanized NSG model of IPF in which im-
mune and non-immune cells derived from explanted IPF
tissue are intravenously administered into NSG mice
and induce lung remodeling that is apparent by day 35
after introduction [17]. To study the role of DNA-PKcs
in humanized NSG mice, mice were intravenously ad-
ministered with IPF cells and starting at day 35 after cel-
lular administration, mice were treated interperitoneally
with 10mg/kg of Nu7441 or saline, twice a week for 4
weeks (Fig. 7a). As aforementioned, Nu7441 is a potent
and highly selective inhibitor of DNA-PK. In this study,
it was used to target injected IPF cells and mimic the
loss of DNA-PK observed in IPF. Nu7441 treatment
did not modulate hydroxyproline levels in humanized
mice relative to the saline-treated groups (Fig. 7b),
αSMA protein levels (Fig. 7c), lung remodeling (Fig.
7d) or transcripts encoding for ACTA2, COL17A1,
COL3A1, VIM, CDKN1A, CDKN1B, CHGA, ENO2,
GLRA1 and NOX4 (Fig. 7e) (n = 4–5 mice per group).
However, in 20% of the humanized NSG mice treated
with Nu7441, there was a mass in the thoracic cavity
(Fig. 7f) (n = 1). IHC analysis on tissue extracted from
this mass showed that cells within this mass highly
expressed human-S100A4 (Fig. 7g), SSEA4 (Fig. 7h), CgA
(Fig. 7i), CCR10 (Fig. 7j) and Ki-67 (Fig. 7k) proteins. Col-
lectively, these results suggest that DNA-PKcs may protect
Fig. 7 DNA-PKcs inhibition in IPF explant cell-humanized NSG mice promoted expansion of SSEA4+ S100A4+ cells. a IPF lung explant cells were
intravenously administered into NSG mice. Thirty-five days after administration, mice were treated interperitoneally with saline or 10 mg/kg of
Nu7441, twice a week for 4 weeks. After a total of 63 days, mice were sacrificed, and their lung tissues were collected for analysis. Shown are the
(b) average hydroxyproline concentration in the lungs of mice and (c) representative western blot of lung lysates from saline and Nu7441 treated
NSG mice for alpha-SMA (αSMA, top) and GAPDH (bottom) proteins and densitometric ratios of αSMA normalized to GAPDH proteins from saline
and Nu7441 treated mice. Data shown are mean ± s.e.m.; n = 4–5/group. One-way ANOVA followed by Tukey’s multiple comparisons test. (d)
Masson’s trichrome staining of naive and IPF lung explant cell–challenged NSG mouse lungs treated with saline or Nu7441. e RNA was extracted
from saline or Nu7441 treated NSG mouse lungs and qPCR analysis was performed for various human transcripts. Shown is the average
expression of the indicated transcripts in Nu7441 relative to saline treated NSG lungs. Data shown are mean ± s.e.m.; n = 4/group. f One out of
five mice receiving Nu7441 developed a mass in the thoracic cavity. g-k Shown are representative images acquired at 50x magnification of the
tissue mass stained for human-S100A4 (g), SSEA4 (h), human-CgA (i), human-CCR10 (j), Ki-67 (k) or IgG control (inlay) antibodies
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against extracellular matrix deposition and the expansion
of mesenchymal progenitor cells in vivo.
Discussion
IPF is a lethal fibrotic lung disease, characterized by exces-
sive ECM deposition leading to the loss of the lung’s archi-
tecture and function. This disease is characterized by
shortened telomeres in structural cells [3, 29–31], senes-
cence of epithelial progenitor and stromal cells [30, 32–39],
microsatellite instability [40, 41] and an increased incidence
of lung cancer [42, 43]. However, mechanisms accounting
for these features in IPF remain elusive. Given the previously
reported role of DNA-PKcs in innate DNA sensing [25, 44],
genomic stability, telomere capping and maintenance, cell
replication and DNA-damage repair [11, 12], we further
assessed both the expression and function of this protein in
IPF. In this report, we observed the reduced expression of
DNA-PK in the lungs of IPF patients and mesenchymal pro-
genitor cells (SSEA4+ cells) and fibroblasts (SSEA4− cells)
from IPF patients. Moreover, targeting DNA-PK in vitro re-
vealed the important role of this kinase in regulating senes-
cence in these cell types.
Because DNA-PKcs has been explored in innate DNA
sensing [11, 12], studies were first performed to assess
the role of this kinase in CpG-mediated fibroblast to
myofibroblast differentiation. Immunofluorescence ana-
lysis suggested that DNA-PKcs primarily localized in the
nucleus of both normal and IPF lung fibroblasts.
Twenty-four hours after CpG treatment, this kinase lo-
calized in endosomal and peri-nuclear regions with rare
localization in the nucleus. Further, we rarely detected
colocalization of CpG-DNA and DNA-PKcs, suggesting
that this kinase may not act as an innate DNA sensor in
lung fibroblasts. Indeed, inhibiting this kinase failed to
modulate CpG-induced Collagen 1, α-SMA and IL-1β
protein expression in lung fibroblasts. Consistently, the
expression of DNA-PKcs transcripts were significantly
reduced in SSEA4+ mesenchymal progenitor cells and fi-
broblasts derived from lung tissues of rapidly progres-
sing IPF patients, where we most consistently observe
robust CpG mediated myofibroblast differentiation [18].
These results suggest that IPF lung fibroblasts may not
utilize DNA-PKcs as an innate DNA sensor.
DNA-PKcs acts as a scaffold and a kinase, where the
loss of its kinase activity leads to telomeric aberrations,
and radiation sensitization due to reduced NHEJ DNA
repair [45–47]. To model the loss of DNA-PKcs in IPF,
we chronically treated human lung fibroblast cultures
with a highly specific small molecule kinase inhibitor,
NU7441 [16]. Chronic treatment of lung fibroblasts with
Nu7441 accelerated fibroblast senescence in vitro as evi-
denced by the increased expression of various senes-
cence markers in these cells. Given the role of DNA-
PKcs in DNA repair and checkpoint signaling during
replication stress [48, 49], this senescence effect may be
due to increased replication stress in the treated cells.
This finding is consistent with other studies showing the
induction of senescence because of replication stress
[50], and suggests that the loss of this kinase may con-
tribute to the abundance of senescent cells in IPF lungs
[30, 32–38]. Surprisingly, in in vivo studies, DNA-PKcs
inhibition via Nu7441 treatment did not change the ex-
pression of senescence markers in the lung tissues. How-
ever, these studies were performed in mice lacking
DNA-PKcs kinase activity (due to a mutation in the gene
encoding for this protein) and thus the lack of any ob-
served effects may be due to the dilution of DNA-PKcs
expressing human cells in the mouse lungs. Interestingly,
20% of humanized NSG mice treated with this inhibitor
showed a marked expansion in SSEA4+ mesenchymal
progenitor cells, which were also positive for CgA,
S100A4 [26], and CCR10. Further, most of the cells
expressed high levels of Ki-67 protein, suggesting a high
proliferative index. Given the role of DNA-PKcs in repli-
cation stress and its role in preventing telomeric fusions
[11, 12], it is possible that targeting this protein in vivo
promoted genomic instability and subsequently in-
creased the proliferation of these progenitor cells. How-
ever, further studies are required to fully address this
possibility since this was observed in only one mouse in
the current study.
Since SSEA4+ cells were expanded in Nu7441-treated
humanized NSG mice, we undertook additional analyses
of these cells to determine what other markers these
progenitor cells expressed [6, 26]. Surprisingly, this ana-
lysis indicated these cells expressed multiple neuroendo-
crine markers. Indeed, pulmonary neuroendocrine cells
were reported to be among the first specialized cell type
to appear during lung development [51]. Further, cell-
tracing studies have indicated that neuroendocrine cells
can give rise to various epithelial cells, including club
cells, ciliated cells in response to naphthalene-induced
injury [52], which is consistent with the co-expression of
various epithelial and neuroendocrine markers in cul-
tured SSEA4+ cells. Nevertheless, in addition to epithe-
lial and neuroendocrine markers, SSEA4+ cells also
expressed stromal markers suggesting that these cells
may also give rise to stromal cells. Interestingly, the
SSEA4+ mesenchymal progenitor cells detected in hu-
manized SCID mice highly expressed the neuroendo-
crine marker, CgA, and there was an expansion of CgA-
expressing cells in IPF lungs. This finding is consistent
with a previous report [53], and suggests that there may
be aberrant neuroendocrine cells in IPF, and DNA-PKcs
regulates the differentiation of SSEA4+ mesenchymal
progenitor cells. Thus, the loss of DNA-PKcs in IPF
might be associated with the emergence of a diverse
array of cell types from SSEA4+ progenitor cells
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including those with epithelial cell, neuroendocrine,
and/or mesenchymal cell properties.
Conclusions
In summary, these results demonstrate that loss of
DNA-PKcs promotes the expansion of SSEA4+ mes-
enchymal progenitor cells and the senescence of fi-
broblasts in IPF. Additional studies are warranted to
further explore the DNA-PKcs-dependent mechanisms
leading to the proliferation of pathologic SSEA4+
mesenchymal progenitor cells and the senescence of
differentiated mesenchymal cells, and whether these
events are modulated by FDA-approved IPF therapeu-
tics including Ofev and Esbriet or other emerging IPF
therapeutics.
Additional files
Additional file 1: Figure S1. Inhibition of DNA-PKcs kinase activity does
not modulate CpG-mediated IL1ß secretion by IPF lung fibroblasts. Lung
fibroblasts were stimulated with 10 μM CpG or 20 ng/ml TGF-ß1 and/or
treated with 500 nM Nu7441 for 24 h. (A-B) Shown is the average
concentration of IL1ß secreted from two senescent IPF lung fibroblasts
lines after stimulation and/or Nu7441 treatment in triplicate. (PDF 42 kb)
Additional file 2: Figure S2. Inhibition of DNA-PKcs ameliorated lung
fibroblast invasive wound healing. Lung fibroblasts were then plated into
96 well plates, scratched using a WoundMaker™ and then layered with 4
mg/ml Matrigel containing vehicle or 500 nM Nu7441. Lung fibroblast
invasive wound healing was monitored using an Incucyte Zoom live cell
imager. Depicted is a kinetic read-out of wound closure (relative to the
initial wound) over 150 h of three normal (A-C) and two IPF (D-E) lung
fibroblasts treated in triplicate. (PDF 239 kb)
Additional file 3: Figure S3. Ingenuity canonical pathways enriched in
Slow-IPF SSEA4+ and SSEA4− cells compared to normal cells. SSEA4+ cells
were sorted from normal and IPF lung fibroblast cultures. RNA was
extracted from the sorted cells SSEA4+ and non-sorted SSEA4− cells and
subject to RNA sequencing analysis as previously described (GSE103488).
(A-B) Shown are Ingenuity canonical pathway analysis of Slow-IPF versus
normal SSEA4+ cells (A) and Slow-IPF versus normal SSEA4− cells (B).
Ingenuity was set to consider transcripts with an FPKM value ≥0.2 and a
fold change ≥1.5 &≤ − 1.5 (A) and FPKM value ≥1 and a fold change
≥1.5 &≤ − 1.5 (B). Percentage depicts the proportion of transcripts from
the transcriptomic analysis that are annotated in the Ingenuity canonical
pathway. The percentage of transcripts that are downregulated or
upregulated in each canonical pathway are depicted in green or red,
respectively. (PDF 793 kb)
Additional file 4: Figure S4. Immunofluorescence IgG control staining
of IPF lung tissues. Normal or IPF lung explants were stained IgG
antibodies followed by fluorescently conjugated secondary antibodies
and microscopy analysis. Representative images from two IPF patients are
shown stained with IgG + Alexa Flour 488 conjugated secondary
antibody (left), IgG + Alexa Flour 594 conjugated secondary antibody
(middle) and the merged composite (right) acquired at 200x
magnification. (PDF 405 kb)
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